RTI-354

RTI-354 is a psychoactive drug and research chemical that was developed in the 1990s by the Research Triangle Institute (RTI). It is part of a series of compounds known as the RTI-phenyltropanes, which are potent inhibitors of the dopamine transporter (DAT). RTI-354 is particularly notable for its high selectivity for the DAT over other monoamine transporters.

Chemistry

RTI-354 is a phenyltropane derivative, which is a class of compounds that includes many potent inhibitors of the dopamine transporter (DAT). The structure of RTI-354 includes a tropane ring, a phenyl ring, and a piperidine ring. The compound is chiral, with the (R)-enantiomer being the more active form.

Pharmacology

RTI-354 acts as a potent and selective inhibitor of the dopamine transporter (DAT), which is responsible for the reuptake of dopamine in the brain. By blocking the reuptake of dopamine, RTI-354 increases the amount of dopamine available in the synaptic cleft, leading to increased dopaminergic activity. This can result in stimulant effects, as well as potential antidepressant and antiparkinsonian effects.

Research and Development

RTI-354 was developed in the 1990s by the Research Triangle Institute (RTI), as part of their research into new treatments for cocaine addiction. The compound was found to have a high selectivity for the DAT over other monoamine transporters, which suggested that it might have a lower risk of side effects compared to other DAT inhibitors. However, further development of RTI-354 was halted due to concerns about its potential for abuse.

See Also

• RTI-336
• RTI-371
• RTI-55

‎